14 Jul 2025
14th of July 2025
Brussels, July 14th, 2025
Poster Presentation at IAS 2025: Results from the “C2C” Study.
High Virologic Suppression and Low Failure Rates Seen with Long-Acting Cabotegravir + Rilpivirine in Treatment-Experienced Virologically Suppressed People Living with HIV: Real-World Data from COMBINE-2 Cohort.
New real-world evidence from the COMBINE-2 cohort, presented at the International AIDS Society Conference (IAS) 2025, shows that people living with HIV (PWH) who were treatment experienced virologically suppressed at initiation maintained high levels of viral suppression and demonstrated high levels of regimen adherence when switched to long-acting (LA) cabotegravir + rilpivirine (CAB+RPV). The findings will be shared in a poster presentation on the 17thof July 2025 from 12.15-13.15 (GMT+2).
The COMBINE-2 study analysed clinical outcomes from 956 treatment-experienced, virologically suppressed individuals across seven European countries - Spain, France, Germany, Belgium, Switzerland, the Netherlands, and the United Kingdom, who initiated CAB+RPV LA between December 2020 and May 2024. Participants were enrolled through the NEAT ID Network.
Key findings include:
99% of individuals with follow-up viral load (VL) testing maintained VL <50 copies/mL at last VL.
92% remained on CAB+RPV LA at time of analysis (median follow-up: 10.2 months).
96% individuals had on-time injections
Virologic suppression remained high at 6, 12, and 24 months (97%, 96%, and 94%, respectively).
Only 0.5% experienced confirmed virologic failure (CVF), with most regaining suppression after switching regimens.
“These real-world results highlight the clinical durability and feasibility of long-acting CAB+RPV for maintaining virologic suppression in diverse populations” said Professor Anton Pozniak, Chief Investigator of the study. “The high rate of virological success underscores the effectiveness of this LA regimen in routine practice.”
The study emphasizes the potential of long-acting injectable therapies to simplify treatment, support adherence, and enhance the quality of life for PWH who are stable and virologically suppressed.
Contributing Sites: North Bristol NHS Trust (Southmead) (UK), Lewisham and Greenwich NHS Trust (UK), Homerton University Hospital (UK), Calderdale and Huddersfield NHS (UK), Hospital de la Santa Creu i Sant Pau (Spain), Eloise (Spain), Hospital Ramon y Cajal (Spain), Hospital General Universitario de Alicante (Spain), Hospital Universitario Vall d'Hebron (Spain), Bellvitge University Hospital (Spain), Hospital del Mar (Spain), Germans Trias i Pujol University Hospital (Spain), Hospital Clinic de Barcelona (Spain), Hopital Europeen Marseille (France), CHU Hotel Dieu Nantes (France), Hopital Lariboisiere (France), Saint-Louis Hospital (France), Hopital de Melun, Groupe hospitalier Sud Ile de France (France), CHU Pontchaillou (France), Hopital Foch (France), GH/Pitié-Salpêtrière (France), Hopital Hotel Dieu service immunoinfectiologie (France), Departement Infectiologie, Hôpital du Bocage (France), Institute of Tropical Medicine Antwerp (Belgium), CHU Saint-Pierre (Belgium), University Hospital Bonn (Germany), University hospital rechts der Isar, Technical University of Munich (Germany), Frankfurt University Hospital (Germany), ICH Study Center (Germany), WIR Walk In Ruhr, Zentrum für Sexuelle Gesundheit und Medizin (Germany), Praxis Jessen2 und Kollegen (Germany), Medical School Hanover (Germany), University Hospital Basel, Departement of Infectious Diseases and Hospital Epidemiology (Switzerland), Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich (Switzerland), Erasmus Medical Centre (Netherlands).
NEAT ID's mission is to support and develop Clinical Research on Infectious Diseases and spread expertise, resources and funds. NEAT ID provides training and mobility of scientists at all levels and foster lasting research collaborations Internationally. Please visit our website for more details: https://www.NEAT-ID.org.
The study is sponsored by and funded by ViiV.
Notes to editors:
1. NEAT ID's mission is to support and develop Clinical Research on Infectious Diseases and spread expertise, resources and funds. NEAT ID provides training and mobility of scientists at all levels and foster lasting research collaborations Internationally. Please visit our website for more details: https://www.NEAT-ID.org
2. Professor Anton Pozniak is a consultant physician in HIV Medicine at the Chelsea and Westminster Hospital, Professor in the Department of Clinical Research at the London School of Hygiene & Tropical Medicine, Past President of the International AIDS Society and NEAT ID. Anton has been an advisor on HIV and AIDS to the UK Government Health Select Committee and a member of the expert advisory group on AIDS for the UK Department of Health. He has published more than 400 peer-reviewed papers, mainly on clinical aspects of HIV treatment and care and HIV-associated tuberculosis.
Media contact: Polly.Parks@NEAT-ID.org +44 07850 695261